N@N

Gregory Renza Initiated (ACAD) at Buy and Held Target at $60 on, Oct 1st, 2019

Gregory Renza of RBC Capital, Initiated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $60 on, Oct 1st, 2019.

Gregory has made no other calls on ACAD in the last 4 months.

There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $28 on, Tuesday, September 3rd, 2019

These are the ratings of the 4 analyists that currently disagree with Gregory

---

• Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $56 on, Monday, September 23rd, 2019
• Marc Goodman of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $50 on, Friday, September 13th, 2019
• Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Tuesday, September 10th, 2019
• Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $60 on, Monday, September 9th, 2019

Contributing Sources

---